Why Raptor Pharmaceuticals (RPTP) Stock Is Gaining Today

NEW YORK (TheStreet) -- Raptor Pharmaceuticals (RPTP) was gaining 21.6% to $10.02 Friday after beating analysts' estimates for earnings and revenue in the second quarter and raising its sales guidance for the year.

For the second quarter the drug manufacturer reported a loss of -15 cents a share, beating analysts' estimates of a loss of -21 cents by 6 cents. The company reported revenue of $16.31 million for the quarter, while analysts surveyed by Thomson Reuters expected revenue of $14.58 million for the quarter.

Report Pharmaceuticals also announced that is now expects net products sales of $65 million to $70 million for the full year, up from $55 million to 65 million.

Must read: Warren Buffett's 25 Favorite Stocks

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners.Click here to see the holdings for FREE.

RPTP ChartRPTP data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners.Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Trade Tussle Sinks Stocks, Oil Slides, Micron, Daimler - 5 Things You Must Know

Trade Tussle Sinks Stocks, Oil Slides, Micron, Daimler - 5 Things You Must Know

Bank of England Holds Rates Steady, But Vote Shift Signals Hawkish Tone

Bank of England Holds Rates Steady, But Vote Shift Signals Hawkish Tone

Futures Fall on Further Trade Rhetoric from China and 4 Other Stories to Watch

Futures Fall on Further Trade Rhetoric from China and 4 Other Stories to Watch

5 Biggest U.S. Tech Stocks Test $4 Trillion Valuation Amid Bullish Nasdaq Run

5 Biggest U.S. Tech Stocks Test $4 Trillion Valuation Amid Bullish Nasdaq Run

Trade War Fear Creeps Back Into Markets on Thursday

Trade War Fear Creeps Back Into Markets on Thursday